do_not_disturb_altRecruitment Complete

Hypertension, pulmonary

Bayer Identifier:

15681

ClinicalTrials.gov Identifier:

NCT02562235

EudraCT Number:

2014-003952-29

EU CT Number:

Not Available
Riociguat in children with pulmonary arterial hypertension (PAH)

Trial purpose

This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study design consisted of a main study part followed by an optional long-term extension part. The main treatment period consisted of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.

Key Participants Requirements

Sex

Both

Age

6 - 17 Years
  • - Children from 6 years to less than 18 years of age with pulmonary arterial hypertension (PAH)
    - Diagnosed with PAH :
     -- Idiopathic (IPAH)
     -- Hereditable (HPAH)
     -- PAH associated with (APAH)
     --- Connective tissue disease
     --- Congenital heart disease with shunt closure more than 6 months ago (no open shunts, confirmed by RHC no less than 4 months after surgery)
    Regardless of the type of PAH, the following findings are not exclusionary:
     --- Patent foramen ovale (PFO) and asymptomatic, isolated, ostium secundum
    atrial septal defect (OS-ASD) ≤ 1 cm (both confirmed by echocardiogram) and not associated with hemodynamic alterations indicative of significant shunt, e.g. Qp/Qs ratio less <1.5:1 are not exclusionary
    - PAH diagnosed by right heart catheterization (RHC) at any time prior to enrolment (for patients with closed shunts – RHC no less than 4 months after surgery)
    - PAH confirmed by a RHC at any time prior to start of study, with mean pulmonary artery pressure (PAPmean) ≥25 mmHg at rest, pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >240 dyn•sec•cm^-5 (i.e., ≥3.0 wood units•m^2)
    - Patients must be on standard of care PAH medications, allowing Endothelin Receptor Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12 weeks prior to baseline visit.
    Two groups of patients will be included:
     --- Prevalent: Patients currently on PAH medication (allowing ERA and/or PCA) who need additional treatment (discretion of the investigator)
     --- Incident: Treatment naïve patients initiated on PAH medication (allowing ERA and /or PCA) and then riociguat added once patients are stable on standard of care
    - WHO functional class I-III
    - Adolescent females of childbearing potential can only be included in the study if a pregnancy test is negative. Adolescent females of childbearing potential must agree to receive sexual counseling and use effective contraception as applicable. ‘Effective contraception’ is defined as progestogen-only hormonal contraception associated with inhibition of ovulation (implant), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), or any combination of adequate methods of birth control (e.g. condoms with hormonal contraception). Agreement to use contraception is required from the signing of the informed consent form up until 4 weeks after the last study drug administration.
    - Young men must agree to use adequate contraception when sexually active.
    - Written inform consent provided and if applicable child assent provided
  • - Concomitant use of the following medications: phosphodiesterase (PDE) 5 inhibitors (such as sildenafil, tadalafil, vardenafil) and non-specific phosphodiesterase (PDE) inhibitors (theophylline, dipyridamole), nitrates or NO donors (such as amyl nitrite) in any form
     -- Pretreatment with NO donors (e.g. nitrates) within the last 2-weeks before visit 1. The use of any drug including NO acutely for testing during catheterization is not an exclusion criterion.
    - Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization or any history of bronchial artery embolization or massive hemoptysis within 3 months prior to screening
    - Systolic blood pressure (SBP) more than 5 mmHg lower than the age-, sex- and height-adapted level of the 50th SBP percentile (NHBPEP, 2004)
    - History of left-sided heart disease, including valvular disease or heart failure
    - Pulmonary hypertension related to conditions other than specified in the inclusion criteria
    - WHO functional class IV
    - Pulmonary veno-occlusive disease
    - Screening aspartate transaminase (AST) and/ or alanine transaminase (ALT) more than 3 times the upper limit of normal (ULN)
    - Severe restrictive lung disease
    - Severe congenital abnormalities of the lung, thorax, and diaphragm
    - Clinically relevant hepatic dysfunction (especially Child Pugh C)
    - Renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73m^2 e.g. calculated based on Schwartz formula)
    - PH associated with idiopathic interstitial pneumonia (PH-IIP)

Trial summary

Enrollment Goal
24
Trial Dates
October 2015 - July 2026
Phase
Phase 3
Could I Receive a placebo
No
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Wojewodzki Szpital Specjalistyczny - WroclawWroclaw, 51-124, Poland
Withdrawn
Instytut "Pomnik – Centrum Zdrowia Dziecka"Warszawa, 04-730, Poland
Withdrawn
Ospedale Pediatrico Bambino GesùRoma, 165, Italy
Active, not recruiting
Azienda Ospedale-Università di Padova - UOC Cardiologia PediatricaPadova, 35128, Italy
Withdrawn
Universitair Medisch Centrum GroningenGRONINGEN, 9713 GZ, Netherlands
Withdrawn
Great Ormond Street Hospital for ChildrenLondon, WC1N 3JH, United Kingdom
Completed
Hacettepe Universitesi Tip FakultesiAnkara, 6100, Turkey
Withdrawn
Izmir Dr. Behcet Uz Cocuk Hastaliklari HastIzmir, 35210, Turkey
Completed
Deutsches Herzzentrum der Charité (DHZC)Berlin, 13353, Germany
Completed
Gottsegen Gyorgy Orszagos Kardiovaszkularis IntezetBudapest, 1096, Hungary
Withdrawn
Hopital Necker les enfants malades - ParisPARIS, 75015, France
Withdrawn
Eberhard-Karls-Universität TübingenTübingen, 72076, Germany
Completed
Universitätsklinikum HeidelbergHeidelberg, 69115, Germany
Withdrawn
Herz- und Diabeteszentrum Nordrhein-Westfalen (HDZ NRW)Bad Oeynhausen, 32545, Germany
Completed
SZTE ÁOK Szent Györgyi Albert Klinikai KozpontSzeged, 6720, Hungary
Withdrawn
Baskent Universitesi Tip Fakultesi HastanesiAnkara, 6490, Turkey
Withdrawn
Hôpital des EnfantsTOULOUSE Cedex 9, 31059, France
Withdrawn
Hopital du Haut LevequePessac, 33604, France
Completed
Universitätsklinikum UlmUlm, 89075, Germany
Withdrawn
Hospital Teresa HerreraA Coruña, 15006, Spain
Completed
Keio University HospitalShinjuku-ku, 160-8582, Japan
Completed
Aichi Children's Health and Medical CenterObu, 474-8710, Japan
Completed
The University of Osaka HospitalSuita, 565-0871, Japan
Completed
National Cerebral and Cardiovascular CenterSuita, 565-8565, Japan
Withdrawn
Hôpital Erasme/Erasmus ZiekenhuisBrussels, 1070, Belgium
Withdrawn
UZ Leuven GasthuisbergLEUVEN, 3000, Belgium
Withdrawn
UZ GentGENT, 9000, Belgium
Withdrawn
Toho University Omori Medical CenterOta-ku, 143-8541, Japan
Withdrawn
Kitasato University HospitalSagamihara, 252-0375, Japan
Withdrawn
Emergency Institute of Cardiovascular Diseases & TransplantTargu Mures, 540136, Romania
Withdrawn
Niculae Stancioiu Heart Institute Cluj-NapocaCluj Napoca, 400001, Romania
Completed
Clínica Imbanaco S.A.SCali, 760042, Colombia
Withdrawn
Fundación Valle de LiliCali, 760032, Colombia
Withdrawn
La Fe University and Polytechnic Hospital | Nephrology DepartmentValencia, 46026, Spain
Completed
Instituto Nacional de Cardiología "Ignacio Chávez"México D.F., 14080, Mexico
Withdrawn
Boston Children's HospitalBoston, 2115, United States
Withdrawn
The Children's HospitalAurora, 80045, United States
Withdrawn
Vanderbilt University Medical SchoolNashville, 37212-1610, United States
Withdrawn
Nationwide Children's HospitalColumbus, 43205-2696, United States
Withdrawn
East Carolina University | Nephrology & HypertensionGreenville, 27834, United States
Withdrawn
National Cheng Kung University HospitalTainan, 704, Taiwan
Completed
Veterans General HospitalKaohsiung City, 813414, Taiwan
Active, not recruiting
Operadora de Hospitales Angeles S. A. de C. V.Huixquilucan, 52763, Mexico
Withdrawn
Fundacion Santa Fe BogotaCundinamarca, TBC, Colombia
Withdrawn
Irmandade da Santa Casa de Misericordia de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica CardiologiaPorto Alegre, 90020-090, Brazil

Primary Outcome

  • Number of participants with any treatment-emergent adverse events
    An adverse event (AE), including AE in relation to a medical device (i.e. Raumedic dosing pipette), is any untoward medical occurrence in a participant administered with a pharmaceutical product and does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose is resulting in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. AEs occurring between start of study drug and up to 2 days after the last dose were defined as treatment-emergent AEs (TEAEs).
    date_rangeTime Frame:
    From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days.
  • Change in heart rate from baseline
    Mean change in heart rate from baseline is reported.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in blood pressure from baseline
    Mean changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline are reported.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in respiratory rate from baseline
    Mean change in respiratory rate from baseline is reported.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Number of subjects with transitions from baseline in bone age compared to chronological age
    X-ray of left hand was performed for each participant and bone age was determined centrally by a specialist. For each participant, the bone age was compared to the chronological age and assigned to one of the categories - "delayed", "in accordance" or "advanced", indicating the advancement or delay in the growth of the bone. Number of participants who transitioned to another category different from baseline was calculated and is reported.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in hematology parameters (platelets) from baseline
    Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in hematology parameters (lymphocytes/leucocytes ratio) from baseline
    Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in hematology parameter (neutrophils/leucocytes ratio) from baseline
    Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in clinical chemistry (alanine aminotransferase) from baseline
    Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in clinical chemistry (aspartate aminotransferase) from baseline
    Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in clinical chemistry (sodium) from baseline
    Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in clinical chemistry (blood urea nitrogen) from baseline
    Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in clinical chemistry (eGFR) from baseline
    Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set. eGFR = estimated glomerular filtration rate
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in clinical chemistry (urea) from baseline
    Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in clinical chemistry (gamma glutamyl transferase) from baseline
    Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Plasma concentration of riociguat at Week 0
    For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week.
    date_rangeTime Frame:
    Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
  • Plasma concentration of riociguat at Week 4
    For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
    date_rangeTime Frame:
    Week 4 (pre-dose)
  • Plasma concentration of riociguat at Week 8
    For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
    date_rangeTime Frame:
    Week 8 (pre-dose)
  • Plasma concentration of BAY60-4552 at Week 0
    BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week
    date_rangeTime Frame:
    Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
  • Plasma concentration of BAY60-4552 at Week 4
    BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
    date_rangeTime Frame:
    Week 4 (pre-dose)
  • Plasma concentration of BAY60-4552 at Week 8
    BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.
    date_rangeTime Frame:
    Week 8 (pre-dose)

Secondary Outcome

  • Change in 6-minute walking distance from baseline
    6-minute walking distance (6MWD) is a exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. An increase in the distance walked indicates improvement in basic mobility.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Number of subjects with change in WHO functional class from baseline
    The World Health Organization (WHO) functional class describes how severe a patient’s pulmonary hypertension (PH) symptoms are. There are four different classes – I is the mildest and IV the most severe form of PH. Number of participants per change in number of classes is reported.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in NT-proBNP from baseline
    Laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were tested for the participants. When both tests were available, NT-proBNP was chosen over BNP and the same test was performed at every required visit.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in BNP from baseline
    Laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were tested for the participants. When both tests were available, NT-proBNP was chosen over BNP and the same test was performed at every required visit.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in quality of life evaluated by SF-10 questionnaire from baseline
    SF-10 is a parent-completed health survey for children that contains 10 questions adapted from the Child Health Questionnaire. It is scored using nom-based scoring to produce physical and psychosocial health summary measures. The possible range for the physical measure is -10.9 to 57.2 scores and the possible range for the psychosocial measure is 8.8 to 62.3 scores. Higher scores indicate more favorable functioning.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in quality of life evaluated by PedsQL scale
    The PedsQL Generic Core Scales were designed to measure health-related quality of life in children and adolescents. It has 4 dimensions: physical functioning, emotional functioning, social functioning and school functioning. 3 Summary Scores of PedsQL were calculated from the scales including total scale score (23 questions), physical health summary score (physical functioning, 8 questions) and psychosocial health summary score (emotional, social and school functioning, 15 questions). Responses of the questions are transformed to a 0-100 scale. Higher scores indicate better quality of life.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Number of subjects with clinical worsening
    Clinical worsening was defined as: hospitalization for right heart failure, death, lung transplantation, Pott’s anastomosis and atrioseptostomy, worsening of pulmonary arterial hypertension (PAH) symptoms, which must include either an increase in World Health Organization (WHO) functional class or appearance/worsening symptoms of right heart failure and need for additional PAH therapy.
    date_rangeTime Frame:
    Up to Week 24 (plus/minus 5 days)
  • Change in estimated right atrial pressure from baseline
    Estimated right atrial pressure was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in left ventricular eccentricity index from baseline
    Left ventricular (LV) eccentricity index (EI) was measured by echocardiography and defined as the ratio of the LV anteroposterior dimension to the septolateral dimension in the parasternal short-axis window by echocardiography. The value of EI greater than 1.0 is abnormal and suggests right ventricle (RV) overload.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in pericardial effusion from baseline
    Pericardial effusion was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in pulmonary artery acceleration time from baseline
    Pulmonary artery acceleration time was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right ventricular cardiac index from baseline
    Right ventricle (RV) cardiac index (CI) was measured by echocardiography and calculated by dividing the cardiac output (stroke volume × heart rate) by the body surface area. The change in RV CI should not be understood solely but associated with other conditions of the participants.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right ventricular cardiac output from baseline
    Right ventricular cardiac output was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right atrial diastolic area from baseline
    Right atrial diastolic area was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right atrial diastolic area index from baseline
    Right atrial (RA) diastolic area index was measured by echocardiography and calculated by dividing the RA area at end-diastole by the body surface area. The RA area index is a reflection of RA volume at end-diastole. The change in the index should not be understood solely but associated with other conditions of the participants.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right atrial systolic area from baseline
    Right atrial systolic area was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right atrial systolic area index from baseline
    Right atrial (RA) systolic area index was measured by echocardiography and calculated by dividing the RA area at end-systole by the body surface area. The RA area index is a reflection of RA volume at end-systole. The change in the index should not be understood solely but associated with other conditions of the participants.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right ventricular fractional area change from baseline
    Right ventricular fractional area change was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right ventricular diastolic area from baseline
    Right ventricular diastolic area was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right ventricular diastolic area index from baseline
    Right ventricular (RV) diastolic area index was measured by echocardiography and calculated by dividing the RV area at end-diastole by the body surface area. The RV area index is a reflection of RV volume at end-diastole. The change in the index should not be understood solely but associated with other conditions of the participants.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right ventricular systolic area from baseline
    Right ventricular systolic area was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in right ventricular systolic area index from baseline
    Right ventricular (RV) systolic area index was measured by echocardiography and calculated by dividing the RV area at end-systole by the body surface area. The RV area index is a reflection of RV volume at end-systole. The change in the index should not be understood solely but associated with other conditions of the participants.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in systolic pulmonary artery pressure from baseline
    Systolic pulmonary artery pressure was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in tricuspid annular plane systolic excursion from baseline
    Tricuspid annular plane systolic excursion (TAPSE) was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)
  • Change in tricuspid regurgitation peak velocity from baseline
    Tricuspid regurgitation peak velocity was measured by echocardiography.
    date_rangeTime Frame:
    Baseline and Week 24 (plus/minus 5 days)

Trial design

Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1

Additional Information

Click here to find information about studies related to Bayer Healthcare products conducted in EuropeClick here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.